Table IV.
Changes in renal function with iloprost use in patients with chronic renal dysfunction (Group I) and normal renal function (Group II)
| Parameters | Group I | Group II | ||||
|---|---|---|---|---|---|---|
| BI |
AI |
P | BI |
AI |
P | |
| Mean (SD) | Mean (SD) | |||||
| Urea | 48.7 (9.5) | 45.1 (8.8) | 0.037 | 29.1 (6.8) | 30.2 (4.0) | 0.292 |
| Creatinine | 1.43 (0.24) | 1.35 (0.18) | 0.017 | 0.73 (0.2) | 0.75 (0.10) | 0.534 |
| GFR CKD-EPI* | 75.5 (4.6) | 76.6 (4.1) | 0.032 | 116 (3.7) | 115 (3.8) | 0.29 |
| Cystatin C | 1.05 (0.27) | 1.01 (0.24) | 0.045 | 0.72 (0.06) | 0.71 (0.04) | 0.168 |
| GFR cystatin C† | 71 (8.9) | 73 (7.8) | 0.041 | 119 (12) | 122 (11) | 0.224 |
| Alb:Cr (urine) | 42.12 (8.7) | 43.1 (8.2) | 0.892 | 9.6 (4.3) | 9.5 (3.7) | 0.324 |
AI = after iloprost; Alb:Cr (urine) = albumin:creatinine ratio (urine); BI = before iloprost; CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; GFR = glomerular filtration rate.
⁎
CKD-EPI equation for estimating glomerular filtration rate expressed for specified race, sex, and serum creatinine in milligrams per deciliter.
†
GFR calculated by using serum cystatin C.